Treatment for LAM with History of Pneumothorax
For patients with LAM who have experienced pneumothorax, pleurodesis should be performed after the initial pneumothorax rather than waiting for recurrence, and sirolimus therapy should be strongly considered both for disease management and pneumothorax prevention 1.
Immediate Pneumothorax Management
When a patient with LAM presents with pneumothorax:
Perform pleurodesis after the first pneumothorax episode rather than adopting a conservative "wait and see" approach 1. This represents a shift from traditional pneumothorax management because LAM patients have exceptionally high recurrence rates.
The recurrence data strongly supports early intervention: conservative therapy alone results in 66% recurrence, while chemical pleurodesis reduces this to 27% and surgical pleurodesis to 32% 2. Both pleurodesis methods are equally effective and substantially superior to observation.
Chemical or surgical pleurodesis are equally effective options - choose based on local expertise and patient factors 2.
Critical Caveat Regarding Lung Transplantation
There is an important trade-off to consider: patients who undergo pleurodesis have significantly higher perioperative bleeding complications if they later require lung transplantation (93% of those with post-transplant bleeding had prior pleurodesis) 2. However, the guideline panel specifically recommends against using prior pleurodesis as a reason to exclude patients from lung transplantation 1. This reflects the reality that preventing recurrent pneumothoraces and their associated morbidity outweighs transplant-related bleeding risks.
Sirolimus Therapy: The Disease-Modifying Approach
Initiate sirolimus therapy for LAM patients with pneumothorax history, as this addresses both the underlying disease and reduces pneumothorax recurrence 3, 4, 5:
Indications for Sirolimus
- Strong recommendation: LAM patients with FEV1 <70% predicted or declining lung function 3
- Additional benefit: Pneumothorax prevention in patients with recurrent episodes 4, 5
Evidence for Pneumothorax Prevention
- Sirolimus significantly reduces pneumothorax recurrence after surgical pleural covering, with 5-year recurrence-free survival of 82.9% when sirolimus is used versus significantly worse outcomes without it (p=0.001) 4
- In case series, patients with recurrent pneumothorax remained pneumothorax-free during sirolimus treatment, with recurrence only when therapy was discontinued or drug levels dropped 5
- Timing matters: Start sirolimus after the pneumothorax is completely resolved 5
Dosing and Monitoring
- Target serum trough levels of 5-15 ng/ml (though lower levels <5 ng/ml may also be effective) 3
- Monitor for common adverse effects: mucositis, diarrhea, nausea, hypercholesterolemia, acneiform rash, lower extremity swelling 3
- Be vigilant for less common but serious effects: ovarian cysts, proteinuria, drug-induced pneumonitis, and infection risk due to immunosuppression 3
Surgical Options for Refractory Cases
For patients with frequent recurrences despite initial pleurodesis:
- Total pleural covering (TPC) or modified TPC are effective surgical options, particularly when combined with post-operative sirolimus therapy 4
- Tunneled indwelling pleural catheters are underutilized but provide long-term management options with mechanical pleurodesis and reduced hospital stays 6
Algorithm Summary
- First pneumothorax: Perform pleurodesis (chemical or surgical) + initiate sirolimus if FEV1 <70% or declining
- Recurrent pneumothorax despite pleurodesis: Ensure sirolimus therapy is optimized with adequate drug levels
- Frequent recurrences on sirolimus: Consider TPC/mTPC with continued sirolimus therapy
- Refractory cases: Tunneled indwelling pleural catheter as alternative
Key Pitfall to Avoid
Do not discontinue sirolimus therapy once started - pneumothorax recurrence is observed when sirolimus is stopped or levels drop significantly 5. This suggests sirolimus provides ongoing protective effects rather than a one-time cure.